secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2026-10-13T16:36:57+00:00
Accession:  0000310158-26-000237
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Merck elects Paul J. Diaz to board effective Nov. 1, 2026; board grows to 14 members
--------------------------------------------------------------------------------

- Paul J. Diaz, managing partner at Cressey & Company, joins Merck's board effective Nov. 1, 2026 and will stand for shareholder election in May 2027.
- Diaz was appointed to both the Audit Committee and the Research Committee of the board.
- Diaz previously served as president and CEO of Myriad Genetics and, before that, as president and CEO of Kindred Healthcare.
- He also sits on the board of Centene Corporation, the Board of Trustees of Johns Hopkins Medicine and the Board of Visitors of Georgetown University Law Center.
- With Diaz's addition the Merck board will consist of 14 members; he receives standard non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/0000310158-26-000237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/mrk-20261009.htm
  HTML page:      https://secwatch.observer/filing/0000310158-26-000237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer